ArticlePDF Available

A Practical Consensus Guideline for the Integrative Treatment of Parkinson's Disease in Shanghai, China

Authors:
  • Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Abstract

Integrative medicine, including traditional Chinese medicine (TCM), is a new concept in clinical practice for the treatment of neurodegenerative and most chronic diseases. However, integrative consensus or a guideline for the management of patients with Parkinson's disease (PD) is still lacking. The aim of this paper is to provide a review of experiences in clinical practice from Chinese neurologists and physicians (including TCM doctors) in Shanghai, China, and try to provide a clinical guideline for the treatment of the complex and progressive disease of PD with integrative medicine. We included the following treatments: common Western medication, surgery, TCM decoction and patent medicines, acupuncture and Tui na, Yoga, Tai chi chuan, hyperbaric oxygenation, rehabilitation, and other complementary and alternative medicines for the integrative management of the disease. Neurologists and physicians in Shanghai, China, and all over the world should pay attention to integrative medicine, which may be a good choice of treatment for PD.
© 2015 S. Karger AG, Basel
2296–7362/15/0022–0056$39.50/0
Review
Integr Med Int 2015;2:56–62
A Practical Consensus Guideline for
the Integrative Treatment of
Parkinson’s Disease in Shanghai, China
Weidong Pan
a Jun Liu
e Xiangjun Chen
h Qiudong Wang
j Yuncheng Wu
f
Yu Bai
b Yi Liu
c Wentao Li
c Wenwei Li
i Canxing Yuan
d Weiguo Hou
k
Xiaoying Bi
k Jianhua Zhuang
l Qin Dong
g Dingfang Cai
i
Specialized Committee of Neuroendocrinology and Specialized Committee of
Neurology, Shanghai Association of Chinese Integrative Medicine;
Subcommittee of Neurology, Shanghai Chinese Medicine Society
a Department of Neurology, Shuguang Hospital,
b Department of Neurology, Putuo District
Center Hospital,
c Department of Neurology, Shanghai Hospital of Traditional Chinese
Medicine, and
d Department of Neurology, Longhua Hospital, Shanghai University of
Traditional Chinese Medicine,
e Department of Neurology, Ruijin Hospital,
f Department of
Neurology, Shanghai First Hospital, and
g Department of Neurology, Renji Hospital,
Shanghai Jiaotong University,
h Department of Neurology, Huashan Hospital, and
i Laborator y for Neurology, Institute of Integrative Medicine, Zhongshan Hospital, Fudan
University,
j Department of Integrative Neurology, Pudong Hospital of Traditional Chinese
Medicine, and
k Department of Neurology, Changhai Hospital, and
l Department of
Neurology, Changzheng Hospital, Third Military Medical University, Shanghai , China
Key Words
Consensus guideline · Parkinson’s disease · Integrative medicine · Traditional Chinese
medicine · Complementary and alternative medicine · Acupuncture · Tai chi chuan · Yoga ·
Preventive treatment
Abstract
Integrative medicine, including traditional Chinese medicine (TCM), is a new concept in clini-
cal practice for the treatment of neurodegenerative and most chronic diseases. However, in-
tegrative consensus or a guideline for the management of patients with Parkinson’s disease
(PD) is still lacking. The aim of this paper is to provide a review of experiences in clinical prac-
tice from Chinese neurologists and physicians (including TCM doctors) in Shanghai, China, and
try to provide a clinical guideline for the treatment of the complex and progressive disease of
PD with integrative medicine. We included the following treatments: common Western med-
ication, surgery, TCM decoction and patent medicines, acupuncture and Tui na, Yoga, Tai chi
chuan, hyperbaric oxygenation, rehabilitation, and other complementary and alternative
Received: June 5, 2015
Accepted after revision: June 7, 2015
Published online: September 12, 2015
Prof. Weidong Pan, MD, PhD
Department of Neurology
Shuguang Hospital, Shanghai University of Traditional Chinese Medicine
Shanghai, 201203 (China)
E-Mail panwd
@ medmail.com.cn
www.karger.com/imi
DOI: 10.1159/000435813
This is an Open Access article licensed under the terms of the Creative Commons Attribution-
NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to
the online version of the article only. Distribution permitted for non-commercial purposes only.
Downloaded by:
198.143.53.33 - 11/3/2015 12:00:19 PM
57
Integr Med Int 2015;2:56 –62
DOI: 10.1159/000435813
Pan et al.: A Practical Consensus Guideline for the Integrative Treatment of Parkinson’s
Disease in Shanghai, China
www.karger.com/imi
© 2015 S. Karger AG, Basel
medicines for the integrative management of the disease. Neurologists and physicians in
Shanghai, China, and all over the world should pay attention to integrative medicine, which
may be a good choice of treatment for PD. © 2015 S. Karger AG, Basel
Background
Integrative treatment for Parkinson’s disease (PD) such as dopaminergic therapy, neuro-
protective therapy, and traditional Chinese medicine (TCM) might be the unmet medical
needs to slow down or stop disease progress
[1, 2] . The current therapies include Western
medicine (oral medicine), surgery, physical therapy (kinesiotherapy), psychological coun-
seling, and nursing care, whereas traditional medicines provide beneficial effects on symptoms
that help to control the classic motor features of the disease (i.e., tremor, rigidity, and brady-
kinesia) as well as the non-motor symptoms, including autonomic disturbance, dementia,
sleep disturbance, psychiatric disorders, and depression; however, eventually, intolerable
disability and invalid clinical effects develop in most patients with PD
[3] . Over the past 3
decades, significant progress has been achieved in the diagnosis and treatment of PD in China.
Not only TCM but also other integrative medicine proved more and more important in treating
the disease in Shanghai, China
[4] . Movement disorder clinics and associated centers only
exist in part of the tertiary hospitals, and the resources cannot satisfy the need of most patients
with PD
[5] . In many cases, both general neurologists and physicians are responsible for the
diagnosis and treatment of PD patients and are sometimes treating them without adhering to
the guidelines. For almost 5 years, the management of PD has been improving. A consensus
was prepared according to the guideline from the Chinese Parkinson’s Disease and Movement
Disorders Society for the management of PD (third edition)
[6] which summarized the inte-
grative clinical research in China
[4, 7–10] . It is important that neurologists and TCM doctors
offer more effective and reasonable integrative treatment to their patients. However, the
opinions of physicians, general neurologists, and movement disorder specialists in the clinical
practice for the treatment of PD are diverse, which will have a significant influence on the
actual benefits of patients suffering from the disease.
Principle of Treatment
Integrative Treatment
Most patients with PD have motor and/non-motor symptoms in the early or later stages
of the disease. These symptoms not only influence the ability to work but also the activities of
daily living (ADL). PD cases should be treated individually, including oral medicine, operations,
exercise, psychotherapy, and health care as effective treatment options. Oral medicine is the
main treatment choice, and surgery, such as deep brain stimulation (DBS), may be initiated as
independent therapy or a complementary and alternative method to assist oral medicine
[11,
12] . So far, all therapies have improved the symptoms of PD, but they could not stop disease
progression. We should thus focus on the long-term management of PD in order to extend the
treatment period, delay disease progression, and decrease the side effects of medical therapy.
Principle of Medication
Both motor and non-motor symptoms can influence the ADL of patients suffering from
PD, and neurologists or physicians should aim to control the symptoms early, thus improving
the ability to work and the ADL. Early diagnosis and early medication can improve symptoms,
Downloaded by:
198.143.53.33 - 11/3/2015 12:00:19 PM
58
Integr Med Int 2015;2:56 –62
DOI: 10.1159/000435813
Pan et al.: A Practical Consensus Guideline for the Integrative Treatment of Parkinson’s
Disease in Shanghai, China
www.karger.com/imi
© 2015 S. Karger AG, Basel
delay progression, and prevent motor fluctuation and dyskinesia. The compound levodopa or
dopamine receptor agonist used for the treatment of motor symptoms should be started at a
small dosage and increased slowly according to the progression of the disease. Individual
medication management may be more effective and lessen the side effects with regard to
tremor (with/without), dementia (with/without), age at morbidity, occupation, combinative
diseases, potential side effects, aspiration, and the economic situation of the patients. Dopa-
minergic treatment should not be stopped abruptly in order to avoid dopaminergic dysregu-
lation syndrome
[6] .
Internal Medicine (Oral Medication)
According to its severity, PD has been divided into two stages – the early stage (Hoehn-
Yahr 1–2.5), and the middle and severe stages (Hoehn-Yahr 3–5).
PD Patients in the Early Stage
As evidence indicates that the development of PD in the early stage is faster than in the
middle and severe stages
[13, 14] , it is necessary to treat PD patients with oral medication in
the early stage, which includes Western medicine and/or TCM and/or other complementary
and alternative medicine (CAM). Dopaminergic medicine and/or monoamine oxidase B inhib-
itors, vitamin E, herbs, complementary nutrition, and even physical therapy (kinesiotherapy),
psychological counseling, and nursing care can be used. The aim of the treatment is to improve
the mild movement disorders, such as rigidity, tremor, and some non-motor symptoms, and
delay disease progression.
In the case of early-onset PD without dementia, we suggest that neurologists or physi-
cians use a non-egret dopamine receptor agonist, such as pramipexole, piribedil, and ropin-
irole, monoamine oxidase B inhibitors, such as selegiline and rasagiline, adamantanamine, or
compound levodopa, such as Madopar or Sinemet combined with or without entacapone [6] .
If the symptom of tremor cannot be controlled, benzhexol is also a good choice. Most tonify-
ing TCM components or patent medicines can be used in treating this stage of PD, such as
‘Liu-Wei-Di-Huang-Wan’ (六味地黃丸), ‘Zhen-Gan-Xi-Feng-Tang’ (鎮肝熄風湯), ‘Tian-
Ma-Gou-Teng-Yin’ (天麻勾藤飲), ‘Ma-Ren-Zi-Pi-Wan’ (麻仁滋脾丸), ‘Cong-Rong-Tong-Bian-
Kou-Fu-Ye’ (蓯蓉通便口服液), and others [4, 12] .
In the case of later-onset PD, cognitive impairment, or dementia, the compound levodopa
is the first-choice treatment. With progression of the disease, dopamine receptor agonist,
monoamine oxidase B inhibition, or compound levodopa combined with entacapone are
beneficial choices. Cholinergic resistance should be avoided, especially for elderly, later-onset
PD patients with cognitive impairment
[6] .
PD Patients in the Middle and Severe Stages
Symptoms will become more complex for patients in the middle and severe stages, due
to the development of the disease, the side effects of medication, and motor complications
such as motor fluctuation and dyskinesia. The scope of treatment in these stages is to improve
the movement disorders, motor complications, and non-motor symptoms.
Motor fluctuations such as end-of-dose deterioration, on-off phenomenon, and dyskinesia
(abnormal involuntary movements) are common motor complications in the severe stages of
PD. Changing the kind of medication as well as modifying the dose and dosing time may help to
improve the complex symptoms. Insect TCM drugs such as stiff silkworm (僵蠶), earthworm
(地龍), scorpio (全蝎), and centipede (蜈蚣), as well as tonifying ‘Gan’ (liver) and ‘Shen’ (kidney)
TCM herbs are helpful in modifying the doses and dosing times of Western medicine adminis-
Downloaded by:
198.143.53.33 - 11/3/2015 12:00:19 PM
59
Integr Med Int 2015;2:56 –62
DOI: 10.1159/000435813
Pan et al.: A Practical Consensus Guideline for the Integrative Treatment of Parkinson’s
Disease in Shanghai, China
www.karger.com/imi
© 2015 S. Karger AG, Basel
tered to these patients. TCM doctors not only use oral TCM decoction or patent medicine, but
they also individually use TCM as external application to improve complex complications. Some-
times, DBS, Tai chi chuan, and acupuncture can be used as additional non-drug treatments.
Traditional Chinese Medicine
The Theory of TCM in PD Treatment
TCM has gained increasing attention in the treatment of PD. Although it is not curative, it
may play a significant role in delaying disease progression and reducing the side effects of
Western medicine, as well as improving the patients’ ability to perform their ADL
[7, 8] . TCM
ameliorates various symptoms, particularly the age-related symptoms that are called ‘Shen xu’
(kidney deficiency) in Chinese. ‘Shen’ (the kidney) denotes a functional visceral system (‘Zang’)
that plays a central role in the regulation of growth, maturation, and aging and is subdivided
into ‘Shen yang’ (kidney ‘yang’) and ‘Shen yin’ (kidney ‘yin’). Kidney ‘yang’ can be described as
the driving force of all metabolic processes that improve the movements of the body. The
production of kidney ‘yin’ is considered to be effective in increasing nutrition to the muscles and
improving the smoothness of body movements by constituting the constructive potential for
the production of kidney ‘yang’. Based on this concept, TCM aims to potentiate the diminishing
vitality of this transformative cycle caused by a decline in the essence (‘Jing’), which is stored in
the kidneys and underpins the functions of both kidney ‘yin’ and ‘yang’ [7] . In TCM theory, most
PD patients (about two thirds) belong to ‘deficiency in ‘‘yin’’ or ‘‘Jing’’ and ‘‘yang’’ or ‘‘Qi’’ in
‘‘Gan’’ (liver) and ‘‘Shen’’ (kidney)’ by TCM ‘Zheng’ classification, whereas the other ‘Zheng’ such
as blood stasis, deficiency in ‘Qi’ with blood, and phlegm are much less than the first ‘Zheng’ [15] .
TCM Treatment in PD
Our consensus guideline suggests that decoction with medicinal ingredients or Chinese
patent medicine tonifying the ‘yin’ and ‘yang’ of ‘Gan’ (liver) and ‘Shen’ (kidney) may be useful
to treat or improve rigidity, tremor, bradykinesia, sleep disorders, constipation, depression,
anorexia, and automatic symptoms using ‘Di-Huang-Yin-Z’ (地黃飲子), ‘Da-Ding-Feng-Zhu’
(大定風珠), ‘Zhen-Gan-Xi-Feng-Tang’ (鎮肝熄風湯), ‘Tian-Ma-Gou-Teng-Yin’ (天麻勾藤飲),
‘Da-Bu-Yin-Wan’ (大補陰丸), ‘Ren-Shen-Yang-Rong-Tang’ (人參養榮湯), and others, according
to the ‘Zheng’ classification of PD
[15] . Other TCM decoctions or patent medicines such as ‘Dao-
Tan-Tang’ (導痰湯), ‘Tian-Wang-Bu-Xin-Dan’ (天王補心丹), ‘Gui-Pi-Tang’ (歸脾湯), ‘Bu-Yang-
Huan-Wu-Tang’ (補陽還五湯), ‘Qi-Ju-Di-Huang-Tang’ (杞菊地黃丸), ‘Ma-Ren-Wan’ (麻仁丸),
‘Yang-Xue-Qing-Nao-Ke-Li’ (養血清腦顆粒), and others may improve some of the other non-
motor symptoms of the other ‘Zheng’ classification patients with PD. If the TCM doctor or
neurologist is an expert in TCM, he may make an individual prescription choosing ingredients
according to the individual manifestation of ‘Zheng’ and the ‘pulse’ properties of the patient.
All of the TCM therapies can be used for all stages and periods of PD
[7, 15–18] ; if the patient
suffers from dysphagia, TCM medication can be taken via a nasogastric tube.
Acupuncture and ‘Tui na’ (推拿, TCM massage) are often used as complementary
treatment for PD patients with motor and non-motor symptoms; sometimes, the two ther-
apies are used in early-onset PD as initial management to delay disease progression
[19] .
Acupuncturists and massagers may choose acupoints according to TCM theory which may
tonify the ‘yin’ and ‘yang’ of ‘Gan’ and ‘Shen’ or which may prompt the blood circulation of the
body and/or remove blood stasis. The acupoints normally used are ‘Chen Shan’ (承山, BL57),
‘Tai Xi’ (太溪, KI3), ‘Tai Chong’ (太衝, LR3), ‘Shen Shu’ (腎腧, BL23), ‘Zu San Li’ (足三里, ST36),
‘San Yin Jiao’ (三陰交, SP6), ‘Xue Hai’ (血海, SP10), ‘Yang Lin Quan’ (陽陵泉, GB34), ‘He Gu’
(合谷, LI4), ‘Qu Chi’ (曲池, LI11), ‘Du Bi’ (犢鼻, ST35), ‘Shou San Li’ (手三里, LI10), ‘Pi Shu’
Downloaded by:
198.143.53.33 - 11/3/2015 12:00:19 PM
60
Integr Med Int 2015;2:56 –62
DOI: 10.1159/000435813
Pan et al.: A Practical Consensus Guideline for the Integrative Treatment of Parkinson’s
Disease in Shanghai, China
www.karger.com/imi
© 2015 S. Karger AG, Basel
(脾腧, BL20), ‘Gan Shu’ (肝腧, BL18), ‘Wei Zhong’ (委中, BL40), ‘Yin Lin Quan’ (陰陵泉, SP9),
‘Yao Yang Guan’ (腰陽關, DU3), ‘Ming Men’ (命門, DU4), ‘Qi Hai’ (氣海, RN6), and ‘Guan Yuan’
(關元, RN4)
[20–26] .
Tai chi chuan is an effective treatment improving the stability of PD patients
[27–29] and
can be used to control some of the non-motor symptoms such as automatic impairment, sleep
disorders, and depression. Any type of Tai chi chuan can be used for the improvement of the
disease. Those PD patients who cannot keep a standing posture for the exercise of Tai chi
chuan may remain seated until they are gradually able to stand up for the training
[28–30] .
The core of Tai chi chuan is to move the body by mind direction slowly, which differs substan-
tially from aerobic and strength exercises
[28] .
Other Integrative Treatment or Exercises
Surgery
Most patients in the mild stage or with early-onset PD react well to anti-parkinsonism
treatment and/or TCM and/or CAM. Surgery may be used in two situations. Firstly, with the
progression of PD, motor fluctuation, dyskinesia, and even on-off phenomenon will occur, and
DBS will be used to improve the movement disorders of the patients
[11] . Secondly, if the
patients suffer from very heavy motor symptoms such as tremor or rigidity, or the medication
used shows a lack of efficacy, they may start treatment with DBS. We emphasize that DBS is most
effective against tremor and rigidity and is not the first choice for posture and balance disorders.
Age and the course of the disease are the selective factors for treatment with DBS
[11, 12] .
Aerobic Exercise, Strength Exercise, Yoga, Hyperbaric Oxygen, Rehabilitation,
Psychological Guidance, and Health Care
These integrative therapies or exercises are helpful in improving rigidity, balance
disorder, and parts of the non-motor symptoms, and some patients have self-initiated these
activities or treatments during all periods or stages of anti-parkinsonism treatment
[31–33] .
Psychological guidance is useful to reduce depression, and health care is important to prevent
inflammation, nutrition impairment, falls, and fractures. These exercises or therapies are not
the main treatment for improving the symptoms of PD
[34–40] .
Supplementary Treatment
Ginkgo supplementary, Ginseng supplementary, Rhodiola rosea supplementary, mela-
tonin, deep sea fish oil, and American ginseng are often used to improve fatigue, memory
impairment, weakness, automatic impairment, and sleep disorders of PD patients, suggested
by family members or patients themselves
[41, 42] . These CAM are not harmful, but there is
still no evidence-based research supporting their intake except for melatonin
[43–45] .
Preventive Treatment
PD is a progressive neurodegenerative disease; previous to morbidity, most patients
have various preclinical symptoms such as sleep disorders, restless leg syndrome, olfactory
dysfunction, and cognitive impairment. With the progression of these symptoms, patients
tend to suffer from PD; our consensus guideline suggests that these patients should be treated
in the preclinical stage to slow down or stop disease progression. Preventive treatment has
two implications
[44, 45] : firstly, to reduce or stop suffering from the disease, and secondly,
to slow down the progression of PD. The TCM compound cream formula (膏方), herbs which
Downloaded by:
198.143.53.33 - 11/3/2015 12:00:19 PM
61
Integr Med Int 2015;2:56 –62
DOI: 10.1159/000435813
Pan et al.: A Practical Consensus Guideline for the Integrative Treatment of Parkinson’s
Disease in Shanghai, China
www.karger.com/imi
© 2015 S. Karger AG, Basel
may tonify the ‘yin’ and ‘yang’ functions of ‘Gan’ and ‘Shen’, vitamin E, Ginkgo supplementary,
Ginseng supplementary, R. rosea supplementary, melatonin, deep sea fish oil, and American
ginseng may partly present alternative preventive therapies
[2, 46, 47] , but there is still a lack
of evidence-based research.
Conclusion
There are no absolute fixed models for the management or treatment of PD, and thus,
patients should be treated individually according to their condition, which may have its own
individual sensitivity and specificity for each patient. Even the same patient may be treated
by different medication in different stages of the disease. The choice of diagnostic methods
and therapeutic strategies for PD varies among physicians, general neurologists, and
movement disorder specialists. Further consensus programs on the diagnosis and management
of PD patients are warranted, especially for physicians and general neurologists caring for PD
patients in China. The aim and scope of this consensus guideline was to emphasize that
neurologists and physicians (including TCM doctors) should pay attention to integrative
therapy in the treatment of PD patients.
References
 1 Olanow CW, Rascol O, Hauser R, Feigin PD, et al: A double-blind, delayed-start trial of rasagiline in Parkinson’s
disease. N Engl J Med 2009;
361: 1268–1278.
 2 Chen X, Pan W: The treatment strategies for neurodegenerative diseases by integrative medicine. Integr Med
Int 2014;
1: 223–225.
 3 Hely MA, Morris JG, Reid WG, Trafficante R: Sydney Multicenter Study of Parkinson’s disease: non-
L -dopa-
responsive problems dominate at 15 years. Mov Disord 2005;
20: 190–199.
 4 Lu H, Pan W, Wang J, Wu C, et al: The current status of integrative therapies in treating Parkinson’s disease in
six general hospitals in Shanghai. Int J Integr Med 2013;
1: 17.
 5 Chen W, Chen S, Xiao Q, Wang G, Chen SD: Current clinical practice for Parkinson’s disease among Chinese physi-
cians, general neurologists and movement disorders specialists: a national survey. BMC Neurol 2012;
12: 155.
 6 Chinese Parkinson’s Disease and Movement Disorders Society of Chinese Medical Association: The guideline
of the treatment for Parkinson’s disease in China (third edition). Chin J Neurol 2014;
47: 428–433.
 7 Pan W, Kwak S, Liu Y, Sun Y, Fang Z, Qin B, Yamamoto Y: Traditional Chinese medicine improves activities of
daily living in Parkinson’s disease. Parkinsons Dis 2011;
2011: 789506.
 8 Pan W, Kwak S, Li G, Chen Y, Cai D: Therapeutic effect of Yang-Xue-Qing-Nao granules on sleep dysfunction in
Parkinson’s disease. Chin Med 2013;
8: 14.
 9 Pan W, Liu J, Wang Q, et al: Clinical Study on chronic pain in Parkinson’s disease. Integr Med Int 2014; 1: 93–101.
10 Pan W, Kwak S, Liu Y, Fang Z, Zhu X, Yamamoto Y: A compound belonging to traditional Chinese medicine
improves nocturnal activity in Parkinson’s disease. Sleep Med 2011;
12: 307–308.
11 Ye W, Norris JM: Deep brain stimulation for Parkinson disease in elderly individuals. JAMA Neurol 2015;
72:
367–368.
12 Odekerken VJ, Boel JA, Geurtsen GJ, Schmand BA, Dekker IP, de Haan RJ, Schuurman PR, de Bie RM; NSTAPS
Study Group: Neuropsychological outcome after deep brain stimulation for Parkinson disease. Neurology
2015;
84: 1355–1361.
13 Athauda D, Foltynie T: The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat Rev Neurol
2015;
11: 25–40.
14 Fahn S: The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Mov Disord
2015;
30: 4–18.
15 Gu C, Yuan C: The study on distribution of Zheng classification for Parkinson’s disease and the treatment
regular pattern in traditional Chinese medicine. Shang Hai Zhong Yi Yao Za Zhi 2013;
7: 12–14.
16 Zhang G, Xiong N, Zhang Z, Liu L, Huang J, Yang J, Wu J, Lin Z, Wang T: Effectiveness of traditional Chinese
medicine as an adjunct therapy for Parkinson’s disease: a systematic review and meta-analysis. PLoS One
2015;
10:e0118498.
17 Li M, Yang MH, Liu Y: Effects of Chinese herbal medicine Bushenhuoxue Granule on quality of life of patients
with Parkinson disease: a randomized, double-blinded and placebo-controlled trial (in Chinese). Zhong Xi Yi
Jie He Xue Bao 2012;
10: 310–317.
Downloaded by:
198.143.53.33 - 11/3/2015 12:00:19 PM
62
Integr Med Int 2015;2:56 –62
DOI: 10.1159/000435813
Pan et al.: A Practical Consensus Guideline for the Integrative Treatment of Parkinson’s
Disease in Shanghai, China
www.karger.com/imi
© 2015 S. Karger AG, Basel
18 Tian YY, Tang CJ, Wu J, Zhou JS: Parkinson’s disease in China. Neurol Sci 2011; 32: 23–30.
19 Eng ML, Lyons KE, Greene MS, Pahwa R: Open-label trial regarding the use of acupuncture and yin tui na in
Parkinson’s disease outpatients: a pilot study on efficacy, tolerability, and quality of life. J Altern Complement
Med 2006;
12: 395–399.
20 Wang H, Liang X, Wang X, Luo D, Jia J, Wang X: Electro-acupuncture stimulation improves spontaneous loco-
motor hyperactivity in MPTP intoxicated mice. PLoS One 2013;
8:e64403.
21 He X, Yan T, Chen R, Ran D: Acute effects of electro-acupuncture (EA) on hippocampal long term potentiation
(LTP) of perforant path-dentate gyrus granule cells synapse related to memory. Acupunct Electrother Res
2012;
37: 89–101.
22 Lu ZY, Zhao H, Wang T, Chen J, Zong L: Effects of acupuncture on behavior and striatal apoptosis in mice with
Parkinson disease (in Chinese). Zhen Ci Yan Jiu 2012;
37: 186–190.
23 Chen YL, Feng WJ, Zhang XL: Parkinson’s disease combined with overactive bladder syndrome treated with
acupuncture and medication (in Chinese). Zhongguo Zhen Jiu 2012;
32: 215–218.
24 Chang XH, Zhang LZ, Li YJ: Observation on therapeutic effect of acupuncture combined with medicine on
Parkinson disease (in Chinese). Zhongguo Zhen Jiu 2008;
28: 645–647.
25 Ulm G: Differential therapy of advanced Parkinson’s disease with special reference to complementary thera-
peutic approaches. Praxis (Bern 1994) 2004;
93: 1869–1872.
26 Huang Y, Jiang XM, Li DJ: Effects on electro-scalp acupuncture on cerebral dopamine transporter in patients
with Parkinson’ s disease (in Chinese). Zhongguo Zhong Xi Yi Jie He Za Zhi 2006;
26: 303–307.
27 Hackney ME, Earhart GM: Tai Chi improves balance and mobility in people with Parkinson disease. Gait
Posture 2008;
28: 456–460.
28 Li F, Harmer P, Liu Y, Eckstrom E, Fitzgerald K, Stock R, Chou LS: A randomized controlled trial of patient-
reported outcomes with tai chi exercise in Parkinson’s disease. Mov Disord 2014;
29: 539–545.
29 Li F, Harmer P, Fitzgerald K, Eckstrom E, Stock R, Galver J, Maddalozzo G, Batya SS: Tai chi and postural
stability in patients with Parkinson’s disease. N Engl J Med 2012;
366: 511–519.
30 Li F: Tai Ji Quan exercise for people with Parkinson’s disease and other neurodegenerative movement
disorders. Int J Integr Med 2013, DOI: 10.5772/56243.
31 Uc EY, Doerschug KC, Magnotta V, Dawson JD, Thomsen TR, Kline JN, Rizzo M, Newman SR, Mehta S, Grabowski
TJ, Bruss J, Blanchette DR, Anderson SW, Voss MW, Kramer AF, Darling WG: Phase I/II randomized trial of
aerobic exercise in Parkinson disease in a community setting. Neurology 2014;
83: 413–425.
32 Tabak R, Aquije G, Fisher BE: Aerobic exercise to improve executive function in Parkinson disease: a case
series. J Neurol Phys Ther 2013;
37: 58–64.
33 Abrantes AM, Friedman JH, Brown RA, Strong DR, Desaulniers J, Ing E, Saritelli J, Riebe D: Physical activity and
neuropsychiatric symptoms of Parkinson disease. J Geriatr Psychiatry Neurol 2012;
25: 138–145.
34 Schenkman M, Hall DA, Barón AE, Schwartz RS, Mettler P, Kohrt WM: Exercise for people in early- or mid-stage
Parkinson disease: a 16-month randomized controlled trial. Phys Ther 2012;
92: 1395–1410.
35 Haralur SB: Clinical strategies for complete denture rehabilitation in a patient with Parkinson disease and
reduced neuromuscular control. Case Rep Dent 2015;
2015: 352878.
36 Ory Magne F, Fabre N, Gu C, Pastorelli C, Tardez S, Marchat JC, Marque P, Brefel Courbon C: An individual reha-
bilitation program: evaluation by Parkinsonian patients and their physiotherapists. Rev Neurol (Paris) 2014;
170: 680–684.
37 Sihvonen AJ, Leo V, Särkämö T, Soinila S: Effectiveness of music in brain rehabilitation. A systematic review
(in Finnish). Duodecim 2014;
130: 1852–1860.
38 Pierobon A, Giardini A, Maestri R, Farina C, Callegari S, Torlaschi V, Bertotti G, Majani G, Frazzitta G: Disexec-
utive functions and depression in patients with Parkinson disease: the impact on rehabilitation outcome. Am
J Phys Med Rehabil 2014;
93: 764–773.
39 Abrantes AM, Friedman JH, Brown RA, Strong DR, Desaulniers J, Ing E, Saritelli J, Riebe D: Physical activity and
neuropsychiatric symptoms of Parkinson disease. J Geriatr Psychiatry Neurol 2012;
25: 138–145.
40 Wahbeh H, Elsas SM, Oken BS: Mind-body interventions: applications in neurology. Neurology 2008;
70: 2321–
2328.
41 Cao F, Sun S, Tong ET: Experimental study on inhibition of neuronal toxical effect of levodopa by Ginkgo biloba
extract on Parkinson disease in rats. J Huazhong Univ Sci Technolog Med Sci 2003;
23: 151–153.
42 Yang SF, Wu Q, Sun AS, Huang XN, Shi JS: Protective effect and mechanism of Ginkgo biloba leaf extracts for
Parkinson disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Acta Pharmacol Sin 2001;
22:
1089–1093.
43 Miller E, Morel A, Saso L, Saluk J: Melatonin redox activity. Its potential clinical applications in neurodegen-
erative disorders. Curr Top Med Chem 2015;
15: 163–169.
44 Breen DP, Vuono R, Nawarathna U, Fisher K, Shneerson JM, Reddy AB, Barker RA: Sleep and circadian rhythm
regulation in early Parkinson disease. JAMA Neurol 2014;
71: 589–595.
45 Videnovic A, Noble C, Reid KJ, Peng J, Turek FW, Marconi A, Rademaker AW, Simuni T, Zadikoff C, Zee PC:
Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol 2014;
71:
463–469.
46 Pan W: Integrative reserve and integrative medicine. Integr Med Int 2014;
1: 127–129.
47 Muzino Y: Recent research progress in and future perspective on treatment of Parkinson’s disease. Integr Med
Int 2014;
1: 67–79.
Downloaded by:
198.143.53.33 - 11/3/2015 12:00:19 PM
... Among those consistently on regular treatments, the decision to seek Chinese medicine may be influenced by factors such as a suboptimal response to conventional antiparkinsonian medications, the "wearing off " phenomenon as PD advances to later stages, and insufficient managements for non-motor symptoms. Early diagnosis and intervention of non-levodopa for PD patients have been recommended (Pan et al., 2015;Tinelli et al., 2016), despite ongoing controversies regarding the timing and strategies for the initial pharmacological therapy for PD (Waller et al., 2021). Factors contributing to the diagnostic delay in PD may include physicians' unfamiliarity with PD symptomology (Wan et al., 2019). ...
Article
Full-text available
Background Parkinson's disease (PD) is a progressive neurodegenerative condition. Chinese medicine therapies have demonstrated effectiveness for PD in controlled settings. However, the utilization of Chinese medicine therapies for PD in real-world clinical practice and the characteristics of patients seeking these therapies have not been thoroughly summarized. Method The study retrospectively analyzed initial patient encounters (PEs) with a first-listed diagnosis of PD, based on electronic medical records from Guangdong Provincial Hospital of Chinese Medicine between July 2018 and July 2023. Results A total of 3,206 PEs, each corresponding to an individual patient, were eligible for analyses. Approximately 60% of patients made initial visits to the Chinese medicine hospital after receiving a PD diagnosis, around 4.59 years after the onset of motor symptoms. Over 75% of the patients visited the Internal Medicine Outpatient Clinic at their initial visits, while a mere 13.85% visited PD Chronic Care Clinic. Rest tremor (61.98%) and bradykinesia (52.34%) are the most commonly reported motor symptoms, followed by rigidity (40.70%). The most commonly recorded non-motor symptoms included constipation (31.88%) and sleep disturbance (25.27%). Integration of Chinese medicine and conventional medicine therapies was the most common treatment method (39.15%), followed by single use of Chinese herbal medicine (27.14%). The most frequently prescribed herbs for PD included Glycyrrhiza uralensis Fisch. ( gan cao ), Astragalus mongholicus Bunge ( huang qi ), Atractylodes macrocephala Koidz. ( bai zhu ), Angelica sinensis (Oliv.) Diels ( dang gui ), Rehmannia glutinosa (Gaertn.) DC. ( di huang ), Paeonia lactiflora Pall. ( bai shao ), Bupleurum chinense DC. ( chai hu ), Citrus aurantium L. ( zhi qiao / zhi shi/chen pi ), Panax ginseng C. A. Mey. ( ren shen ), and Poria cocos (Schw.) Wolf ( fu ling ). These herbs contribute to formulation of Bu zhong yi qi tang (BZYQT). Conclusion Patients typically initiated Chinese medical care after the establishment of PD diagnosis, ~4.59 years post-onset of motor symptoms. The prevalent utilization of CHM decoctions and patented Chinese herbal medicine products, underscores its potential in addressing both motor and non-motor symptoms. Despite available evidence, rigorous clinical trials are needed to validate and optimize the integration of CHM, particularly BZYQT, into therapeutic strategies for PD.
... Several interventions, including acupuncture, biofeedback, and manual therapy, were mentioned in part of a CPG endorsed by the Canadian Neurological Sciences Federation and Parkinson Society Canada in 2011, but with the caveat that the evidence for their use was insufficient and in need of update (Grimes et al., 2012). Another CPG for integrative interventions published in 2015 included a comprehensive CAM intervention-specific CPG for IPD but was a consensus-based guideline that was not developed on the basis of the current best clinical evidence (Pan et al., 2015). An up-to-date, evidencebased, specific CPG on CAM interventions for IPD is needed to provide clinical evidence that can assist both health care professionals and patients when making a decision whether to include CAM interventions in their long-term strategy for management of the disease. ...
Article
Full-text available
Patients with idiopathic Parkinson’s disease (IPD) require long-term care and are reported to use complementary and alternative medicine (CAM) interventions frequently. This CAM-specific clinical practice guideline (CPG) makes recommendations for the use of CAM, including herbal medicines, acupuncture, moxibustion, pharmaco-acupuncture, and qigong (with Tai chi) in patients with IPD. This guideline was developed using an evidence-based approach with randomized controlled trials currently available. Even though this CPG had some limitations, mainly originating from the bias inherent in the research on which it is based, it would be helpful when assessing the value of the CAM interventions frequently used in patients with IPD.
... For example, the most common neurological disease, Parkinson's disease (PD), is often accompanied by depression. Depression is one of the common non-motor symptoms of PD and can even occur before the onset of PD motor symptoms [11]. The pathological changes of PD are mainly characterized by dopamine depletion in the nigra-corpus striatum system, and dopamine pathways in the midbrain edge and midbrain cortex indirectly affect behavior and cognition. ...
Article
Full-text available
Due to the “stigma” of neuropsychological and psychogenic disorders in China, patients with psychological and affective disorders mostly prefer to go to general hospitals or integrative medicine hospitals, while the majority of patients with mental disorders in the department of internal medicine are treated in the department of neurology. At present, there are few physicians with the ability to diagnose and treat neuropsychiatric diseases properly in the neurological department of general hospitals in China, and the diagnosis and treatment experience of mental diseases is insufficient. At the same time, the diagnosis and treatment of comorbid patients with internal diseases and mental disorders are more complicated. The psychology departments in general hospitals or mental health centers also have a limited ability to diagnose and treat comorbid diseases relating to internal medicine and mental disorders together. Therefore, this article reviews the current status of diagnosis and treatment of neuropsychiatric and mental disorders in general hospitals or integrative medicine hospitals.
... Tian-Ma-Gou-Teng-Yin was prescribed for neurodegenerative diseases (Chik et al., 2013) such as AD Lin et al., 2016) and Parkinson's disease (PD) (Pan et al., 2015), and also the prevention of hypertension . Upon previously detected disease modules, a network illustration of potential interactions between herbs and AD, hypertension related gene targets was constructed to speculate the synergistic effect of herb formula (Figure 4). ...
Article
Full-text available
Traditional Chinese medicine (TCM) is typically prescribed as formula to treat certain symptoms. A TCM formula contains hundreds of chemical components, which makes it complicated to elucidate the molecular mechanisms of TCM. Here, we proposed a computational systems pharmacology approach consisting of network link prediction, statistical analysis, and bioinformatics tools to investigate the molecular mechanisms of TCM formulae. Taking formula Tian-Ma-Gou-Teng-Yin as an example, which shows pharmacological effects on Alzheimer’s disease (AD) and its mechanism is unclear, we first identified 494 formula components together with corresponding 178 known targets, and then predicted 364 potential targets for these components with our balanced substructure-drug–target network-based inference method. With Fisher’s exact test and statistical analysis we identified 12 compounds to be most significantly related to AD. The target genes of these compounds were further enriched onto pathways involved in AD, such as neuroactive ligand–receptor interaction, serotonergic synapse, inflammatory mediator regulation of transient receptor potential channel and calcium signaling pathway. By regulating key target genes, such as ACHE, HTR2A, NOS2, and TRPA1, the formula could have neuroprotective and anti-neuroinflammatory effects against the progression of AD. Our approach provided a holistic perspective to study the relevance between TCM formulae and diseases, and implied possible pharmacological effects of TCM components.
... A prospective double-blind controlled study with consecutive enrollment of 96 subjects affected by idiopathic PD was carried out in patients admitted to the Department of Neurology of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine ( Table 1). The diagnosis of PD was established when two of the main symptoms (bradykinesia, tremor, rigidity, and postural reflex abnormality) were presented [5]. The patients were at least 40 years of age and were evaluated in the middle of their levodopa dose cycle at maximal mobility ("on") for the severity of parkinsonism. ...
Article
Full-text available
Aims . To evaluate the efficacy of Lian-Se formula (LSF), one Chinese herb formulation for treating sialorrhea and frequent overnight urination in patients with Parkinson’s disease (PD). Methods . 96 PD patients suffering from sialorrhea and/or frequent nighttime urination were divided into two groups: an LSF group ( n = 48) treated with LSF for 6 weeks and a placebo group ( n = 48) treated with a placebo formula whose appearance and taste were the same as LSF for 6 weeks. All patients were treated by standard antiparkinsonism medicine according to the PD guideline of China. The changes of the quantity of saliva (QS) (mL), frequency of nighttime urination (FNU) and early sleep activity (ESA), and nocturnal activity (NA) by analyzing actigraphic records as the primary results and the total score of unified Parkinson’s disease rating scale (UPDRS) and the Epworth Sleepiness Scale (ESS) as the secondary results were used to evaluate the clinical efficacy in both groups. Results . There were no significant differences in the baseline values of QS, FNU, NA, ESA, UPDRS total score, and ESS between the two groups. At the end of week 6, the QS, FNU, NA, and ESA in the LSF group showed superior results to those of the placebo group with no differences in the total UPDRS score between the two groups during the investigation. The ESS was significantly improved at the end of week 6 compared with the baseline and the placebo group. Laboratory test results indicated there were no side effects in either group. Conclusion . The findings of LSF treatment have clear clinical effects in patients with sialorrhea and frequent overnight urination. LSF thus appears to be a potential choice as an additional drug that can improve the sialorrhea and frequent overnight urination symptoms of PD patients.
Article
Parkinson’s disease (PD) is a common neurodegenerative disorder, affecting up to 10 million people worldwide according to the Parkinson’s Disease Foundation. Epidemiological and genetic studies show a preponderance of idiopathic cases and a subset linked to genetic polymorphisms of a familial nature. Traditional Chinese medicine and Ayurveda recognized and treated the illness that Western Medicine terms PD millennia ago, and descriptions of Parkinson’s symptomatology by Europeans date back 2000 years to the ancient Greek physician Galen. However, the Western nosological classification now referred to in English as “Parkinson’s disease” and the description of symptoms that define it, are accredited to British physician James Parkinson, who in 1817 authored The Shaking Palsy. Later in the nineteenth century, French neurologist Jean-Martin Charcot re-labeled paralysis agitans “Parkinson’s disease” and over a century of scientific research ensued. This review discusses European, North American, and Asian contributions to the understanding and treatment of PD from ancient times through the twentieth century.
Article
Full-text available
Background/Aims: Pain in Parkinson's disease (PD) may be more distressing than that in other nonmotor disabilities. The aims of the present study were to assess the prevalence and identify the epidemiological characteristics of PD-related pain among patients with idiopathic PD in Shanghai, China. Methods: A total of 1,058 patients with definite idiopathic PD were investigated using a structure questionnaire in 12 hospitals in Shanghai. The severity of their motor disorders, antiparkinson treatments, and pain-related observations, such as time points for the onset of pain, duration and degree, body localization, external influences, and treatments for pain, were collected for analysis. Results: Approximately 28% (296 subjects) of all PD patients suffered from PD-related pain. Female patients with pain had a higher age level, were older at PD onset, had a higher frequency of pain, a higher frequency of pain before the onset of PD symptoms, a longer duration of pain, and a higher incidence of pain in the early stage compared to male patients. Larger levodopa-equivalent doses, higher frequencies of sleep disorders and/or motor fluctuation, and/or dyskinesia were found in patients with pain compared to patients without pain. The most frequent pain type was musculoskeletal pain followed by dystonia. The male group had a much shorter pain duration than the female group. The patients experienced more pain before taking antiparkinson drugs compared to after treatment. Conclusion: Chronic PD-related pain is a frequent complaint and complex in PD. The challenge of managing pain in PD patients will hopefully someday result in specific and effective treatment strategies.
Article
Full-text available
If a person has a bigger face, is he or she less prone to suffer from cognitive disorders than a person with a smaller face? Is this possible? If someone has a higher education and higher income, are they less likely to suffer from cognitive disorders than others. Is this possible, too? The answer to both questions is: yes, it is possible [1, 2] .We can observe many cases around us in which a very heavy smoker does not get lung cancer even though he or she may have had chronic lung injury for a long time. On the other hand, someone may only smoke a little or once in a while but may get lung cancer. People of the same family and nationality, in the same environment, eating the same food and even of the same age and with the same habits often have different disease morbidities. What is the reason?The ability to resist morbidity is termed integrative reserve. For example, two people can have the same degree of Alzheimer’s disease pathology, but one can appear much more demented than the other. The idea behind cognitive reserve is that the brain actively attempts to compensate for pathology. Some people are able to compensate better, for example, by using more efficient brain networks or alternate networks, and may be able to function normally despite the pathology. People with more neurons might be able to lose more of them before showing a clinical deficit [3] .Integrative reserve is not resistibility and immunity, it is reserve ability or capacity. Nation-ality, gender, area, smoking, lifestyle, vascular risk factors, aging, physical activity, weight, income and even education level might be reserve factors of disease morbidities. If something can influence the reserve ability, it can be considered a reserve factor. If our body is infected or injured by pathogenic factors, pathological changes will occur, but sometimes we do not become ill immediately. With the development of pathogenic factors, differences in reserve ability decide whether we will suffer from these diseases or not. Based on many reserve factors, we have different morbidity thresholds, and the buffering capacity is the integrative reserve.Other systems, not only cognitive disorders, also have a reserve, and our body has many types of reserves. Heart failure reserve has been studied in heart rate variability research; if a subject has a 1/f-type temporal scaling heart rate, he or she has a stronger reserve to delay
Article
Full-text available
Idiopathic Parkinson disease (PD) is a common neurodegenerative disease that seriously hinders limb activities and affects patients' lives. We performed a meta-analysis aiming to systematically review and quantitatively synthesize the efficacy and safety of traditional Chinese medicine (TCM) as an adjunct therapy for clinical PD patients. An electronic search was conducted in PubMed, Cochrane Controlled Trials Register, China National Knowledge Infrastructure, Chinese Scientific Journals Database and Wanfang data to identify randomized trials evaluating TCM adjuvant therapy versus conventional treatment. The change from baseline of the Unified Parkinson's Disease Rating Scale score (UPDRS) was used to estimate the effectiveness of the therapies. Twenty-seven articles involving 2314 patients from 1999 to 2013 were included. Potentially marked improvements were shown in UPDRS I (SMD 0.68, 95%CI 0.38, 0.98), II (WMD 2.41, 95%CI 1.66, 2.62), III (WMD 2.45, 95%CI 2.03, 2.86), IV (WMD 0.32, 95%CI 0.15, 049) and I-IV total scores (WMD 6.18, 95%CI 5.06, 7.31) in patients with TCM plus dopamine replacement therapy (DRT) compared to DRT alone. Acupuncture add-on therapy was markedly beneficial for improving the UPDRS I-IV total score of PD patients (WMD 10.96, 95%CI 5.85, 16.07). However, TCM monotherapy did not improve the score. The effectiveness seemed to be more obvious in PD patients with longer adjunct durations. TCM adjuvant therapy was generally safe and well tolerated. Although the data were limited by methodological flaws in many studies, the evidence indicates the potential superiority of TCM as an alternative therapeutic for PD treatment and justifies further high-quality studies.
Article
Full-text available
To the Editor We read with great interest the article by DeLong et al¹ regarding deep brain stimulation (DBS), an established surgical solution for the motor symptoms of Parkinson disease.² They conducted a large nonrandomized clinical trial in which they demonstrated that comparable results are achieved with DBS in patients older than 75 years, contrary to popular belief. We consider this study a significant milestone: it lucidly shows us that despite our preconceptions, we can achieve decent results in elderly individuals for the treatment of PD and, more broadly, in the neurosurgical domain. However, before this study is used as a model for future trials, we would like to make 3 methodological observations.
Article
Full-text available
Objective: To investigate the current use of Western medicine and integrative therapies in the treatment of patients with Parkinson's disease (PD). Methods: A cross- sectional, multicentre clinical epidemiological survey was conducted in six hospitals in Shanghai. We investigated the varieties and frequencies of use of prescriptions of Chinese herb decoctions and compounds as well as the frequencies of other selected therapies. Results: All of the patients with PD were treated by Western medicine, in which 30.16% of them were treated by Western medicine only while 68.24% were treated by one or two forms of traditional Chinese medicine (TCM) and a few were treated by Tai Chi quan or rehabilitation therapy combined with Western medicine. Chinese herb decoctions such as Tian-ma Gou-teng Decoction, Liu-wei Di-huang Decoction, Si-jun-zi Decoction, Da-ding-feng Zhu, etc., and Chinese herb compounds such as Liu-wei Di- huang pill, Huang-xing Run-chang tablet, Cong-rong Tong-bian liquid, Qi-ju Di-huang pill and Dan-lou tablet, all have a higher frequency of utilization. The purposes behind taking TCM mainly focus on the common symptoms of PD patients, such
Article
Full-text available
The dentist has a large role in geriatric health care for the ever increasing elder population with associated physical and neurological disorders. The Parkinson disease is progressive neurological disorder with resting tremor, bradykinesia, akinesia, and postural instability. The psychological components of disease include depression, anxiety, and cognitive deficiency. Poor oral hygiene, increased susceptibility for dental caries, and periodontal diseases predispose them to early edentulism. The number of Parkinson affected patients visiting dental clinic seeking complete denture is growing. This case report explains the steps involved in the complete denture rehabilitation of Parkinson patient. The effective prosthesis will help in alleviating functional, aesthetic, and psychological disabilities of the patient.
Article
To assess the neuropsychological outcome 12 months after bilateral deep brain stimulation (DBS) of the globus pallidus pars interna (GPi) or subthalamic nucleus (STN) for advanced Parkinson disease. We randomly assigned patients to receive either GPi DBS or STN DBS. Standardized neuropsychological tests were performed at baseline and after 12 months. Patients and study assessors were masked to treatment allocation. Univariate analysis of change scores indicated group differences on Stroop word reading and Stroop color naming (confidence interval [CI] 1.9-10.0 and 2.1-8.8), on Trail Making Test B (CI 0.5-10.3), and on Wechsler Adult Intelligence Scale similarities (CI -0.01 to 1.5), with STN DBS showing greater negative change than GPi DBS. No differences were found between GPi DBS and STN DBS on the other neuropsychological tests. Older age and better semantic fluency at baseline predicted cognitive decline after DBS. We found no clinically significant differences in neuropsychological outcome between GPi DBS and STN DBS. No satisfactory explanation is available for the predictive value of baseline semantic fluency for cognitive decline. This study provides Class I evidence that there is no large difference in neuropsychological outcome between GPi DBS and STN DBS after 12 months. The study lacks the precision to exclude a moderate difference in outcomes. © 2015 American Academy of Neurology.